- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-VTNC/ VTN/ V75 functional antibody
Anti-VTNC/ VTN/ V75 functional antibody for cell culture, ELISA & in-vivo assay
Go to VTN/VTN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE0548-Ab-1/ GM-Tg-hg-SE0548-Ab-2 | Anti-Human VTN monoclonal antibody | Human |
| GM-Tg-rg-SE0548-Ab-1/ GM-Tg-rg-SE0548-Ab-2 | Anti-Rat VTN monoclonal antibody | Rat |
| GM-Tg-mg-SE0548-Ab-1/ GM-Tg-mg-SE0548-Ab-2 | Anti-Mouse VTN monoclonal antibody | Mouse |
| GM-Tg-cynog-SE0548-Ab-1/ GM-Tg-cynog-SE0548-Ab-2 | Anti-Cynomolgus/ Rhesus macaque VTN monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE0548-Ab-1/ GM-Tg-felg-SE0548-Ab-2 | Anti-Feline VTN monoclonal antibody | Feline |
| GM-Tg-cang-SE0548-Ab-1/ GM-Tg-cang-SE0548-Ab-2 | Anti-Canine VTN monoclonal antibody | Canine |
| GM-Tg-bovg-SE0548-Ab-1/ GM-Tg-bovg-SE0548-Ab-2 | Anti-Bovine VTN monoclonal antibody | Bovine |
| GM-Tg-equg-SE0548-Ab-1/ GM-Tg-equg-SE0548-Ab-2 | Anti-Equine VTN monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-SE0548-Ab-1/ GM-Tg-hg-SE0548-Ab-2; GM-Tg-rg-SE0548-Ab-1/ GM-Tg-rg-SE0548-Ab-2; GM-Tg-mg-SE0548-Ab-1/ GM-Tg-mg-SE0548-Ab-2; GM-Tg-cynog-SE0548-Ab-1/ GM-Tg-cynog-SE0548-Ab-2; GM-Tg-felg-SE0548-Ab-1/ GM-Tg-felg-SE0548-Ab-2; GM-Tg-cang-SE0548-Ab-1/ GM-Tg-cang-SE0548-Ab-2; GM-Tg-bovg-SE0548-Ab-1/ GM-Tg-bovg-SE0548-Ab-2; GM-Tg-equg-SE0548-Ab-1/ GM-Tg-equg-SE0548-Ab-2 |
| Products Name | Anti-VTN monoclonal antibody |
| Format | mab |
| Target Name | VTN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-VTN benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-SE0548-Ag-1 | Recombinant multi-species VTNC/ VTN/ V75 protein |
| ORF Viral Vector | vGMLP001205 | human VTN Lentivirus particle |
| ORF Viral Vector | pGMLP001205 | human VTN Lentivirus plasmid |
| ORF Viral Vector | pGMLPm001542 | mouse Vtn Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001542 | mouse Vtn Lentivirus particle |
Target information
| Target ID | GM-SE0548 |
| Target Name | VTN |
| Gene ID | 7448,22370,29169,708499,480621,101100765,507525,100059034 |
| Gene Symbol and Synonyms | Aa1018,V75,VN,VNT,VTN |
| Uniprot Accession | P04004 |
| Uniprot Entry Name | VTNC_HUMAN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000109072 |
| Target Classification | N/A |
The target: VTN, gene name: VTN, also named as V75, VN, VNT. The protein encoded by this gene functions in part as an adhesive glycoprotein. Differential expression of this protein can promote either cell adhesion or migration as it links cells to the extracellular matrix through a variety of ligands. These ligands include integrins, plasminogen activator inhibitor-1, and urokinase plasminogen activator receptor. This secreted protein can be present in the plasma as a monomer or dimer and forms a multimer in the extracellular matrix of several tissues. This protein also inhibits the membrane-damaging effect of the terminal cytolytic complement pathway and binds to several serpin serine protease inhibitors. This protein can also promote extracellular matrix degradation and thus plays a role in tumorigenesis. It is involved in a variety of other biological processes such as the regulation of the coagulation pathway, wound healing, and tissue remodeling. The heparin-binding domain of this protein give it anti-microbial properties. It is also a lipid binding protein that forms a principal component of high density lipoprotein. [provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
